Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
RADNOR, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its...
View HTML
Toggle Summary Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
Platform Presentation of Phase 2 Data in Fragile X Syndrome RADNOR, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced...
View HTML
Toggle Summary Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
RADNOR, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Lorianne K....
View HTML
Toggle Summary Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
RADNOR, Pa., April 10, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented Phase 1 clinical data showing the safety and tolerability of...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
RADNOR, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results
RADNOR, Pa., March 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities...
View HTML
Toggle Summary Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
Data Published in Neuropharmacology RADNOR, Pa., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of...
View HTML
Toggle Summary Marinus Appoints Michael R. Dougherty to its Board of Directors
RADNOR, Pa., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R....
View HTML
Toggle Summary Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase 2 open-label study evaluating its CNS-selective GABA A...
View HTML
Toggle Summary Marinus Provides Business Outlook for 2017
Several Data Milestones Anticipated With Ganaxolone RADNOR, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a...
View HTML